AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend. Fair value range: low $153, high $255, with mid-point at $204.
Fairly valued at current levels; maintain position.
Fair value
$204
Margin of safety
+0.5%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$202.71Price
FV $203.67
High $254.75
AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend.
Intellectual property and robust pipeline
Intellectual property and robust pipeline in immunology, oncology, and aesthetics.
Scale and distribution networks globally
Scale and distribution networks globally.
Cycle upside
Aging population and increasing prevalence of autoimmune diseases drive secular volume growth. Innovation in targeted therapies commands premium pricing.
§2 Bärenszenario
A severe margin contraction driven by pricing reform and aggressive biosimilar uptake stresses FCF. Debt load from Allergan acquisition amplifies equity risk, constraining dividend growth and leading to a structural multiple de-rating.
Based on our latest independent analysis, ABBV trades close to fair value. The current price is $203 versus a composite fair-value midpoint of $204 (range $153–$255), which implies roughly 0.5% upside to the midpoint.
Our composite fair-value range for ABBV is $153–$255, with a midpoint of $204. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for AbbVie Inc.'s archetype.
Our current rating for ABBV is Hold with a confidence score of 88/100. Hold. The current valuation perfectly balances the robust immunology transition against the ongoing Humira patent cliff. Collect the dividend while monitoring pipeline execution. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for AbbVie Inc. are: Accelerated Humira Erosion; Skyrizi/Rinvoq Disappointment; Pricing Regulation. The single biggest risk is Accelerated Humira Erosion: Biosimilar competition erodes Humira revenues significantly faster than projected, compressing margins.
Our current rating for ABBV is Hold, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($153–$255) versus the current price of $203.
AbbVie Inc. is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for ABBV.
